Loading...
Even amid the long-standing debate over the usefulness of prostate-specific antigen (PSA)-based prostate cancer screening, the consensus in the urologic oncology community is that curative-intent local treatment should be considered only for men with life expectancies ≥10 years. However, estimating the survival of individual patients is a daunting challenge, likely resulting in broad variability in the selection of candidates for therapy.
To provide estimates of survival based on patient age, tumor stage and grade, and comorbidities, investigators linked Surveillance, Epidemiology, and End Results (SEER) data to Medicare files to conduct a 10-year competitive-risk analysis involving 19,639 men (age, ≥66) who received diagnoses of localized p…